DDReg pharma

Quailty Driven by Passion

Submit Query

Author name: development

Fostering Medical Innovation with Expedited Review Processes

Blogs, Regulatory /

2023 marked a significant year in the pharmaceutical industry as the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved an impressive 55 novel drugs. These approvals, including new molecular entities (NMEs) and new therapeutic biologics, underscore the FDA’s commitment to advancing patient care with innovative therapies. Over […]

Fostering Medical Innovation with Expedited Review Processes Read More »

Easing Requirements for Minimal Risk Clinical Trials

Blogs, Clinical Regulatory, Regulatory /

Expediting clinical trials that post minimal risk is important to advance healthcare & drug development. In particular, easing the requirements for informed consent regarding trial participants- for minimal risk clinical trials- can help expedite the entire clinical development process and ultimately accelerate the overall regulatory approval process. Earlier the US FDA’s regulations allowed for exceptions

Easing Requirements for Minimal Risk Clinical Trials Read More »

Standardizing Real World Data for Drug and Biological Product Submissions

Blogs, Regulatory /

Real world data (RWD) is proving to be an important source of information for applications such as New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), biologic license applications (BLAs) and Investigational New Drug (IND) applications. With RWD being submitted as relevant “study data”, certain agencies like the US FDA, require that the format should

Standardizing Real World Data for Drug and Biological Product Submissions Read More »

Streamlining Clinical Investigations for Medical Devices

Blogs, Clinical Regulatory, Medical Device, Regulatory /

Clinical investigations for medicinal devices are critical in order to advance healthcare and patient safety. Streamlining clinical investigations help accelerate the delivery of innovative solutions to patients, which ensures timely access to devices that would help diagnose and treat diseases. Simplifying regulatory processes, enhancing stakeholder engagement, and aligning with global practices fosters more rapid approvals.

Streamlining Clinical Investigations for Medical Devices Read More »

DDReg Managing Director wins ET RE Pharma “Woman Icon of the Year” Award 2024

News and Events /

The 4th edition of the Economic Times (ET) RE Pharma Awards was held on the 20th of January 2024 to recognize excellence within the Indian Pharmaceutical Industry. Indeed, these awards have developed into a prestigious platform to celebrate the outstanding achievements by stakeholders in the pharmaceutical sector of India- both, organizations, and individuals. Continuing its

DDReg Managing Director wins ET RE Pharma “Woman Icon of the Year” Award 2024 Read More »

Third Party Review Program for Medical Devices

Blogs, Medical Device, Regulatory /

The onset of the pandemic highlighted many obstacles pertaining to medical devices used to detect and diagnose the virus, SARS-CoV-2. Many device manufacturers emerged with their concerns and requested for “Emergency-Use Authorization” (EUA) for their in vitro diagnostic medical devices used to help detect the virus. In response to this request, the US FDA provided

Third Party Review Program for Medical Devices Read More »

SwissMedic: Strengthening Safety Signal Reporting for Veterinary Products

Blogs, Pharmacovigilance /

Efficiently detecting safety signals for veterinary products is crucial for safeguarding animal health and ensuring the well-being of both animals and humans. Rapid identification of potential risks allows for timely intervention, preventing widespread harm. Recognizing the significance of this, global authorities are actively working to fortify safety signal reporting. Establishing regulatory guidelines ensures a standardized

SwissMedic: Strengthening Safety Signal Reporting for Veterinary Products Read More »

Effective Communication for the Safe Use of Biosimilars

Blogs, Labeling /

Biosimilars and interchangeability with biologics has been a topic of discussion for regulatory authorities worldwide, including their definitions and varying requirements per regions. However, a key requirement or standard for interchangeability requires applicants to provide sufficient information to demonstrate bio similarity. This reflects in the biosimilars labelling requirements where prescription drug and biological product labels

Effective Communication for the Safe Use of Biosimilars Read More »

Indian Pharmacopoeia Commission: Safety Alert for Mefenamic Acid

Blogs, Pharmacovigilance /

Pharmacovigilance in India has come a long way over the last few years especially for proactively detecting safety signals for pharmaceutical products. It is an indispensable component of the pharmaceutical industry in India, ensuring the safety and efficacy of drugs in the market. This comprehensive field includes various sub-categories, each contributing to the overall goal

Indian Pharmacopoeia Commission: Safety Alert for Mefenamic Acid Read More »

The Use of Item Response Theory in Clinical Outcome Assessments

Blogs, Clinical Regulatory, Regulatory /

Clinical outcome assessments (COAs) are a critical component of clinical trials and regulatory submissions for regulatory agencies like the US FDA. The US FDA defines a COA as a “measure that describes or reflects how a patient feels, functions, or survives”; COAs provide important information to the US FDA on the effectiveness of therapies so

The Use of Item Response Theory in Clinical Outcome Assessments Read More »